Board logo

subject: Aarkstore Enterprise---diabetes Market Forecast To 2013 [print this page]


Which companies are poised to dominate the diabetes market? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety issues affect drug profitability over the long term?

A veteran analysts answer these questions and more by placing critical drug information in a relevant industry-wide context. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers all in one, easy-to-read format.

From showing the most accurate sales projections and pipelines to identifying market threats and opportunities, Diabetes Market Forecast to 2013 provides teams with a hard-hitting, penetrating analysis of the global diabetes market. For reliable evidence to support key resource allocation decisions, this is the only resource youll need.

Give your brand team all the diabetes data it needs to make critical product decisions!

Table of Contents :

Type I Antidiabetic Treatments

Traditional Insulins

Novolin

Humulin

Short-Acting Insulin Analogs

Novolog

Humalog

Apidra

Long-Acting Insulin Analogs

Levemir

Lantus

Other Drugs

Symlin

Technosphere

Teplizumab

Otelixuzumab

TT-223

Type II Antidiabetic Treatments

DPP-4 Inhibitors

Januvia (includes Janumet)

Galvus (includes Eucreas)

Alogliptin

Onglyza

GLP-1 Analogs

Byetta (includes Byetta Long-Acting Release)

Liraglutide

AVE0010

Syncria

Tapsoglutide

SGLT-2 Inhibitors

AVE2268

Remogliflozin

Dapagliflozin

Sulfonylureas

Amaryl

Glucotrol

For more information please contact :

http://www.aarkstore.com/reports/Diabetes-Market-Forecast-to-2013-6771.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise




welcome to loan (http://www.yloan.com/) Powered by Discuz! 5.5.0